fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Clobazam

All products: Limited Use (codes 23)

Teva-Clobazam · DIN 02238334 · 10 mg · tablet

Limited Use, Reason for Use code 23 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 23 required
Write on scriptReason for Use code 23 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Ontario Limited Use criteria, code 23
Reason for Use code 23 As adjunctive therapy in the treatment of seizure disorders where control by other listed anticonvulsants has been unsatisfactory. Coverage limit: Because a large number of patients will become refractory to the anticonvulsant effects of the drug over a period of time, the effectiveness of this drug must be re-evaluated after a period of six months. Coverage limit: LU Authorization Period: Indefinite
1 brand, same coverage
Teva-Clobazam · DIN 02238334 Manufacturer: Teva Canada Limited; listing date 1999-04-15 Health Canada: Marketed since 2017-01-10 · brand TEVA-CLOBAZAM · ATC N05BA09 CLOBAZAM · form Tablet · route Oral · ingredients CLOBAZAM 10 MG · company Teva canada limited · schedule Targeted substances (cdsa iv)
Re-check Health Canada status and shortages (live) · Health Canada product record

Teva-Clobazam: Formulary list price $0.22 per unit (the source does not state the unit; exact figure $0.2197). What the ministry pays, not the patient.

Ministry pays: $0.2197 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02238334)

Source record
DIN 02238334: Teva-Clobazam Raw flags: sec12=Y, sec3=Y Item: 281200061; group id 425; item number 1058; lccId 00071; manufacturer id TEV Source form: Tab; strength: 10mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $0.2197; ministry $0.2197 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02238334 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=61740
Interchangeable products
Apo-Clobazam · DIN 02244638 · $0.2197 Frisium · DIN 02221799 · not recorded
Shortage status: resolved shortage (ended April 29, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02238334
Shortage record checked October 6, 2026
Other drugs in the same formulary class (28:12 Anticonvulsants) and how they are covered

Matched class: 28:12 Anticonvulsants

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: CLONAZEPAM, DIVALPROEX SODIUM, ETHOSUXIMIDE, VALPROATE SODIUM Some products covered without a code (check the product listing): CARBAMAZEPINE, GABAPENTIN, LAMOTRIGINE, PHENYTOIN (DIPHENYLHYDANTOIN), PHENYTOIN (DIPHENYLHYDANTOIN) SODIUM, PREGABALIN, PRIMIDONE, TOPIRAMATE, VALPROIC ACID 28:12 Anticonvulsants

CARBAMAZEPINE

· 15 products · Listed, not a benefit (3), General benefit (6), Temporary benefit (2), Limited Use, codes 67 (4) · strengths: 100mg, 200mg, 400mg, 100mg/5mL · Chew Tab, ER Tab, LA Tab, Oral Susp, Tab

CLONAZEPAM

· 9 products · General benefit · strengths: 0.5mg, 2mg · Tab

DIVALPROEX SODIUM

· 9 products · General benefit · strengths: 125mg, 250mg, 500mg · Ent Tab

ETHOSUXIMIDE

· 4 products · General benefit · strengths: 250mg, 50mg/mL · Cap, O/L

GABAPENTIN

· 69 products · General benefit (49), Off-Formulary Interchangeable, not an ODB benefit (20) · strengths: 100mg, 300mg, 400mg, 600mg, 800mg · Cap, Tab

LAMOTRIGINE

· 28 products · General benefit (25), General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (3) · strengths: 25mg, 100mg, 150mg · Tab

PHENYTOIN (DIPHENYLHYDANTOIN)

· 4 products · General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (2), General benefit (2) · strengths: 6mg/mL, 25mg/mL, 50mg · O/L, Tab

PHENYTOIN (DIPHENYLHYDANTOIN) SODIUM

· 4 products · General benefit (3), Limited Use, codes 481, 657 (1) · strengths: 30mg, 100mg, 50mg/mL · Cap, Inj Sol (Preservative Free)

PREGABALIN

· 102 products · General benefit (93), Off-Formulary Interchangeable, not an ODB benefit (9) · strengths: 25mg, 50mg, 75mg, 150mg, 225mg, 300mg · Cap

PRIMIDONE

· 4 products · General benefit (2), Listed, not a benefit (2) · strengths: 125mg, 250mg · Tab

TOPIRAMATE

· 54 products · Limited Use, codes 321 (2), Off-Formulary Interchangeable, not an ODB benefit (3), General benefit (49) · strengths: 15mg, 25mg, 50mg, 100mg, 200mg · Sprinkle Cap, Tab

VALPROATE SODIUM

· 5 products · General benefit · strengths: 50mg/mL · O/L Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 28:12 and 11 more
Full class listing Related classes: 28:08 Analgesics, 28:10 Opiate Antagonists, 28:16 Psychotherapeutic Agents, 28:20 C.N.S. Stimulants, 28:24 Sedatives and Hypnotics, 28:36 Antiparkinsonian Agents, 28:92 Miscellaneous Central Nervous System Drugs Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE TEVA-CLOBAZAM (clobazam) is indicated for: adjunctive therapy in patients with epilepsy who are not adequately stabilized with their current anticonvulsant therapy. Geriatrics (> 65 years of age): The efficacy of TEVA-CLOBAZAM in adults aged 65 and over has not been established (see WARNINGS AND PRECAUTIONS and ACTION AND CLINICAL PHARMACOLOGY sections). Long-term use of TEVA-CLOBAZAM should be avoided in elderly patients. Enhanced monitoring is recommended (see WARNINGS AND PRECAUTIONS, Falls and fractures; DOSAGE AND ADMINISTRATION, Dosing considerations). https://pdf.hres.ca/dpd_pm/00064104.PDF PM date: December 22, 2021 Source product: TEVA-CLOBAZAM; DIN 02238334; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.